𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Synthesis of [2H3]-labelled sulfamethoxazole and its main urinary metabolites

✍ Scribed by Georg Heinkele; Thomas E. Mürdter

Publisher
John Wiley and Sons
Year
2007
Tongue
French
Weight
103 KB
Volume
50
Category
Article
ISSN
0022-2135

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Sulfamethoxazole was labelled at positions 3, 5, and 4′ by H/D exchange in a mixture of 5% ^2^H~2~SO~4~ and 95% ^2^H~2~O (v/v) under reflux for 72h with good isotope incorporation and acceptable yield. Subsequently, [^2^H~3~]‐sulfamethoxazole‐N~1~‐glucuronide and [^2^H~3~]‐N~4~‐acetyl‐sulfamethoxazole were synthesized. Copyright © 2007 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Synthesis of [2H3]-dextromethorphan and
Synthesis of [2H3]-dextromethorphan and its major urinary metabolites [2H3]-dextrorphan and [2H3]-dextrorphan-β-glucuronide
✍ Georg Heinkele; Gerhard Schänzle; Thomas E. Mürdter 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 77 KB

## Abstract Starting from dextromethorphan, [^2^H~3~]‐dextrorphan‐__β__‐glucuronide was synthesized in four steps with [^2^H~3~]‐dextromethorphan and [^2^H~3~]‐dextrorphan as intermediates with an overall yield of 11%. Copyright © 2002 John Wiley & Sons, Ltd.

Synthesis of 2H- and 14C-labeled fexinid
Synthesis of 2H- and 14C-labeled fexinidazole and its primary metabolites labeled with 2H
✍ E. Fontana; Alberto Pignatti; Serena Venegoni; Michael A. Bray 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 419 KB

The preparation of deuterium labeled fexinidazole, a 5‐nitroimidazole drug candidate for the treatment of Human African Trypanosomiasis, and its two main metabolites (fexinidazole sulfoxide and fexinidazole sulfone) for use as internal standards for liquid chromatography‐mass spectrometry are report

Synthesis of 2H- and 13C-labelled suniti
Synthesis of 2H- and 13C-labelled sunitinib and its primary metabolite
✍ Paul W. Elsinghorst; Michael Gütschow 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 210 KB

## Abstract Sunitinib (Sutent^®^, Pfizer) was approved in 2006 for the treatment of gastrointestinal and renal cancer. Isotope‐labelled derivatives have already been prepared for PET and ADME radiography. The preparation of ^13^C‐ and ^2^H‐labelled internal standards of sunitinib (SU11248) and its

Syntheses of [2H3, 15N], [14C]Nexavar™ a
Syntheses of [2H3, 15N], [14C]Nexavar™ and its labeled metabolites
✍ U. Pleiss; M. Gerisch; D. Seidel 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 150 KB 👁 1 views

Nexavar TM , Sorafenib tosylate (BAY 43-9006 tosylate) is a potent small molecule Raf kinase inhibitor for the treatment of hyperproliferative disorders such as cancer. Both radiolabeled and stable isotope labeled compounds were required for drug absorption, distribution, metabolism and excretion (A